证券代码：001323 证券简称：慕思股份 公告编号：2023-025 慕思健康睡眠股份有限公司 关于监事会换届选举的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 慕思健康睡眠股份有限公司（以下简称"公司"）第一届监事会任期将于 2023 年 9 月 3 日届满，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规以及《公司章程》的有关规定，公司 监事会应于任期届满前进行换届选举。公司于 2023 年 8 月 16 日召开第一届监事 会第十七次会议，审议通过了《关于监事会换届选举非职工代表监事的议案》。 现将相关情况公告如下： 公司第二届监事会将由 3 人组成，其中非职工代表监事 2 人、职工代表监事 1 人。经公司监事会审核：同意提名罗振彪先生、雷华先生为公司第二届监事会 非职工代表监事候选人，上述候选人简历详见附件。上述非职工代表监事候选人 尚须提交公司 2023 年第一次临时股东大会审议，并采用累积投票制进行选举， 任期自公司股东 ...

慕思健康睡眠股份有限公司独立董事 关于第一届董事会第二十二次会议相关事项的独立意见 根据中国证监会《上市公司治理准则》《深圳证券交易所上市公司自律监管 指引第 1 号—主板上市公司规范运作（2022 年修订）》《慕思健康睡眠股份有 限公司章程》《慕思健康睡眠股份有限公司独立董事制度》等相关规定，我们作 为慕思健康睡眠股份有限公司（以下简称"公司"）的独立董事，在认真查阅了 公司提供的相关资料、了解相关情况后，本着谨慎性原则，基于独立、客观判断 的立场，对公司第一届董事会第二十二次会议审议的相关事项发表独立意见如下： 一、关于董事会换届选举非独立董事、独立董事的独立意见 二、关于部分募集资金投资项目延期的独立意见 我们认为：公司本次部分募集资金投资项目延期事项，是根据项目实际情况 作出的审慎决定，符合公司实际经营的需要和长远的发展规划，符合中国证券监 督管理委员会和深圳证券交易所关于上市公司募集资金管理的相关规定，公司本 次部分募集资金投资项目延期事项履行了必要的决策程序，不存在改变或变相改 变募集资金投向和其他损害公司股东，特别是中小股东利益的情形，不会对公司 的正常运营产生重大不利影响。我们一致同意公司本次 ...

慕思健康睡眠股份有限公司 证券投资、期货和衍生品交易管理制度 慕思健康睡眠股份有限公司 证券投资、期货和衍生品交易管理制度 第一章 总 则 第一条 为规范慕思健康睡眠股份有限公司（以下简称"公司"或"本公司"） 及控股子公司的证券投资、期货和衍生品交易行为，建立健全有序的投资决策管 理机制，有效防范投资风险，保证公司资金、财产的安全，维护股东和公司的合 法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券 交易所股票上市规则》（以下简称"《股票上市规则》"）、《深圳证券交易所 自律监管指引第 1 号——主板上市公司规范运作》《深圳证券交易所上市公司自 律监管指引第 7 号——交易与关联交易》等法律法规、规范性文件及《慕思健康 睡眠股份有限公司章程》（以下简称"《公司章程》"）的规定，结合公司实际 情况，特制定本制度。 第二条 本制度适用于公司及控股子公司的证券投资、期货和衍生品交易行 为。未经公司同意，控股子公司不得进行证券投资、期货与衍生品交易。公司参 股公司进行证券投资、期货和衍生品交易，对公司业绩可能造成较大影响的，公 司应当参照本制度相关规定，履行信息披露义务。 第三条 本制度所称证 ...

慕思健康睡眠股份有限公司（以下简称"公司"）第一届监事会任期将于 2023 年 9 月 3 日届满，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律法规以及《公司章程》的有关规定，公司 监事会应于任期届满前进行换届选举。公司第二届监事会将由三名监事组成，其 中一名为职工代表监事，由公司职工代表大会选举产生。公司于 2023 年 8 月 16 日召开职工代表大会，经与会职工代表认真审议，同意选举汪玉芳女士为公司第 二届监事会职工代表监事。 证券代码：001323 证券简称：慕思股份 公告编号：2023-026 慕思健康睡眠股份有限公司 关于选举第二届职工代表监事的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次职工代表大会会议选出的职工代表监事，将与公司 2023 年第一次临时 股东大会选举产生的其他两名非职工代表监事共同组成公司第二届监事会，任期 与第二届监事会一致。 2023 年 8 月 17 日 附件： 汪玉芳女士，1983 年 ...

慕思健康睡眠股份有限公司 独立董事提名人声明与承诺 提名人 慕思健康睡眠股份有限公司董事会 现就提名 向振宏 为 慕思健康 睡眠 股份有限公司第 二 届董事会独立董事候选人发表公开声明。被提名人已 书面同意作为 慕思健康睡眠 股份有限公司第 二 届董事会独立董事候选人(参 见该独立董事候选人声明)。本次提名是在充分了解被提名人职业、学历、职称 、详细的工作经历、全部兼职、有无重大失信等不良记录等情况后作出的，本提 名人认为被提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券 交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如 下事项： 一、被提名人已经通过股份有限公司第 一 届董事会提名委员会或者独立董 事专门会议资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立 履职情形的密切关系。 是 □否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等规定不得 担任公司董事的情形。 是 □否 如否，请详细说明：______________________________ 三、被提名人符合中 ...

招商证券股份有限公司 关于慕思健康睡眠股份有限公司 部分募集资金投资项目延期的核查意见 招商证券股份有限公司（以下简称"招商证券"或"保荐机构"）作为慕思 健康睡眠股份有限公司（以下简称"慕思股份"或"公司"）首次公开发行股票 并上市的保荐机构，根据《证券发行上市保荐业务管理办法（2023 年修订）》、 《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求（2022 年修订）》、《深圳证券交易所股票上市规则（2023 年修订）》、《深圳证券交 易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等有关规定，对慕 思股份部分募集资金投资项目延期的事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2022]831 号文核准，并经深圳证券交 易所同意，本公司由主承销商招商证券股份有限公司通过深圳证券交易所系统采 用网下向符合条件的投资者询价配售与网上向持有深圳市场非限售 A 股和非限 售存托凭证市值的社会公众投资者定价发行相结合的方式，向社会公众公开发行 人民币普通股（A 股）4,001 万股，发行价为每股人民币 38.93 元。截至 2022 年 6 ...

证券代码：001323 证券简称：慕思股份 慕思健康睡眠有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------|-----------------------|-------------|--------|----------| | | | | 编号： | 2023-002 | | | □特定对象调研 | □分析师会议 | | | | | □媒体采访 | 业绩说明会 | | | | 投资者关系活 | | | | | | | □新闻发布会 □路演活动 | | | | | 动类别 | | | | | | | □现场参观 | | | | □其他 活动参与人员 通过全景网参与公司"2022 年度网上业绩说明会"的投资者 时间 2023 年 5 月 8 日 15:00-17:00 地点 全景网"投资者关系互动平台"（https://ir.p5w.net） 董事长兼总经理王炳坤先生、独立董事奉宇先生、独立董事向振宏先 上市公司人员 生、董事会秘书赵元贵先生、财务总监李立发先生、保荐代表人邓永 姓名 辉先生。 形式 网络在线交流形式 1、 请介绍一下你公 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year growth of 15%[15]. - The net profit attributable to shareholders was RMB 200 million, an increase of 10% compared to the previous year[15]. - The company's operating revenue for 2022 was ¥5,812,675,105.79, a decrease of 10.31% compared to ¥6,481,040,857.11 in 2021[6]. - Net profit attributable to shareholders was ¥708,923,751.74, representing a 3.27% increase from ¥686,443,004.23 in the previous year[6]. - The net cash flow from operating activities decreased by 34.91% to ¥647,441,433.57 from ¥994,612,484.60 in 2021[6]. - Basic earnings per share for 2022 were ¥1.87, down 2.09% from ¥1.91 in 2021[6]. - The total assets at the end of 2022 increased by 29.22% to ¥5,812,842,531.74 from ¥4,498,298,427.75 at the end of 2021[6]. - The net assets attributable to shareholders rose by 69.84% to ¥4,358,353,143.59 from ¥2,566,163,587.76 in 2021[6]. - The company achieved a revenue of 5.813 billion yuan in 2022, a decrease of 10.31% compared to the previous year, while net profit attributable to shareholders increased by 3.27% to 709 million yuan[89]. - Total revenue for 2022 was approximately ¥5.81 billion, a decrease of 10.31% compared to ¥6.48 billion in 2021[102]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[15]. - Future guidance estimates a revenue growth of 18% for 2023, with a projected net profit margin of 15%[15]. - The company plans to enhance its high-end brand image and focus on becoming a leader in the premium mattress segment in 2023[164]. - The company will pursue both organic growth and acquisitions to expand its market presence and capitalize on the booming sleep economy in China[162]. - The company aims for a revenue and net profit growth of 10%-20% in 2023 compared to 2022, contingent on various market conditions[164]. Product Development and Innovation - New product launches are expected to contribute an additional RMB 300 million in revenue in 2023, driven by innovative sleep solutions[15]. - The company has invested RMB 50 million in R&D for new technologies related to smart sleep products[15]. - The company has established a research and development innovation center to coordinate product and technology development, implementing an integrated product development process to enhance innovation capabilities[74]. - The company is developing new products such as portable outdoor mattresses and smart baby protection mattresses to enhance product lines and market competitiveness[115]. - The smart mattress product has undergone 8 years of R&D and is now in its eighth generation, featuring AI technology and sleep monitoring capabilities[171]. Customer Engagement and Sales Channels - User data indicates a growth in active customers, reaching 1.5 million, which is a 20% increase from the previous year[15]. - The company has established a comprehensive multi-channel sales network covering the entire country, integrating distribution, e-commerce, direct supply, and direct sales[52]. - The e-commerce channel's main business revenue from the official flagship store model accounted for approximately 94% of the total e-commerce sales during the reporting period[70]. - The company has established over 5,600 offline specialty stores across various channels, including direct sales and e-commerce platforms, enhancing its nationwide sales network[80]. Research and Development - The company has added 645 new patents during the reporting period, bringing the total to 2,561 valid intellectual property rights[95]. - The company has formed partnerships with top universities and companies, including Huawei, to strengthen its research and development capabilities[84]. - The R&D center improved product development efficiency by standardizing materials and processes, resulting in a reduction in new product development cycles[93]. - The company is focusing on personalized mattress design based on individual physiological data to improve sleep quality and product competitiveness[113]. Risk Management and Compliance - The management has identified risks related to supply chain disruptions and is implementing strategies to mitigate these risks[5]. - The company is aware of macroeconomic risks that could impact sales and is taking measures to strengthen internal controls and market analysis[175]. - The company strictly adheres to corporate governance regulations, ensuring a complete and clear internal governance structure[186]. Financial Management and Investments - The company raised a total of RMB 155,758.93 million through the issuance of 40.01 million shares at a price of RMB 38.93 per share, with a net amount of RMB 147,714.38 million after deducting issuance costs of RMB 8,044.55 million[134]. - The company has not utilized any raised funds for repaying bank loans or supplementing working capital, maintaining a focus on project investments[138]. - The company reported a total of RMB 2,178.14 million in interest income from the special account, net of bank fees, as of December 31, 2022[135]. Market Trends and Industry Insights - The mattress industry in China is the largest producer and the second-largest consumer globally, with significant growth potential due to low market penetration and high replacement cycles[153]. - E-commerce retail in China has grown significantly, with online retail sales of physical goods rising from 10.80% of total retail sales in 2015 to 27.21% in 2022, providing new sales channels for the mattress industry[157]. - The global smart furniture market is projected to grow from $24.1 billion in 2016 to $53.5 billion in 2022, reflecting a compound annual growth rate of 14.21%[158].

Financial Performance - The company's revenue for Q1 2023 was ¥957,196,805.44, a decrease of 23.10% compared to ¥1,244,772,745.73 in the same period last year[15] - Net profit attributable to shareholders for Q1 2023 was ¥101,266,788.82, down 18.40% from ¥124,100,304.76 in the previous year[15] - The net profit after deducting non-recurring gains and losses was ¥97,712,218.67, representing a 21.00% decrease from ¥123,685,058.19 year-on-year[15] - Basic and diluted earnings per share for Q1 2023 were both ¥0.25, a decline of 26.47% from ¥0.34 in the previous year[15] - The weighted average return on equity was 2.30%, down 2.42% from 4.72% in the same period last year[15] - The total comprehensive income for the current period is ¥100,053,544.33, compared to ¥124,107,715.29 in the previous period, reflecting a decrease of approximately 19.4%[30] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥344,574,318.58, compared to a negative cash flow of ¥312,054,829.28 in the same period last year, marking a 210.42% increase[15] - Cash and cash equivalents increased by 53.70% to ¥2,722,102,309.18 from ¥1,771,027,257.63, primarily due to net cash flow from operating activities[35] - Cash flow from operating activities generated a net amount of ¥344,574,318.58, a significant recovery from a negative cash flow of ¥-312,054,829.28 in the previous period[47] - The company reported cash and cash equivalents at the end of the period amounting to ¥2,644,063,850.64, compared to ¥891,781,986.78 at the end of the previous period, indicating a substantial increase[47] - The company reported a significant increase in cash flow from other operating activities, rising to ¥26,429,580.22 from ¥8,378,324.26, an increase of about 215.56%[47] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥6,030,975,552.60, an increase of 3.75% from ¥5,812,842,531.74 at the end of the previous year[15] - The company's total liabilities amount to ¥1,572,568,864.68, an increase from ¥1,454,489,388.15 in the previous period[29] - The total equity attributable to the parent company is ¥4,458,406,687.92, up from ¥4,358,353,143.59, showing an increase of about 2.3%[29] - The total current assets rose to ¥3,362,604,705.71, compared to ¥3,166,752,012.85, marking an increase of about 6.18%[41] - The total liabilities increased significantly, with accounts payable rising by 354.03% to ¥329,767,063.31 from ¥72,631,139.10, mainly due to increased settlements with suppliers using bank acceptance bills[35] Operating Costs and Expenses - Total operating costs for the current period amount to ¥840,017,586.61, down from ¥1,093,750,850.29, reflecting a reduction of about 23.2%[29] - Research and development expenses for the current period are ¥34,087,515.27, slightly up from ¥32,551,963.68 in the previous period, reflecting an increase of approximately 4.7%[29] - The company reported a financial expense of -¥9,969,332.30, compared to a financial expense of ¥2,475,285.34 in the previous period, indicating a significant improvement[29] - Financial expenses decreased significantly by 502.75% to -¥9,969,332.30 from ¥2,475,285.34, mainly due to an increase in bank interest income[36] Other Income and Gains - The company reported non-recurring gains totaling ¥3,554,570.15 for the quarter, including government subsidies and other income[17] - Other income increased by 127.19% to ¥3,255,026.85 from ¥1,432,746.71, primarily due to an increase in government subsidies[36] - The company has not identified any non-recurring gains that were classified as regular gains according to the relevant disclosure guidelines[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,845, with the largest shareholder holding 37.50%[36]